

SCIENTIFIC REPORTS



OPEN

Content and activity of human liver microsomal protein and prediction of individual hepatic clearance *in vivo*

Received: 16 May 2015
Accepted: 30 October 2015
Published: 04 December 2015

Haifeng Zhang*, Na Gao*, Xin Tian, Tingting Liu, Yan Fang, Jun Zhou, Qiang Wen, Binbin Xu, Bing Qi, Jie Gao, Hongmeng Li, Linjing Jia & Hailing Qiao

The lack of information concerning individual variation in content and activity of human liver microsomal protein is one of the most important obstacles for designing personalized medicines. We demonstrated that the mean value of microsomal protein per gram of liver (MPPGL) was 39.46 mg/g in 128 human livers and up to 19-fold individual variations existed. Meanwhile, the metabolic activities of 10 cytochrome P450 (CYPs) were detected in microsomes and liver tissues, respectively, which showed huge individual variations (200-fold). Compared with microsomes, the activities of liver tissues were much suitable to express the individual variations of CYP activities. Furthermore, individual variations in the *in vivo* clearance of tolbutamide were successfully predicted with the individual parameter values. In conclusion, we offer the values for MPPGL contents in normal liver tissues and build a new method to assess the *in vitro* CYP activities. In addition, large individual variations exist in predicted hepatic clearance of tolbutamide. These findings provide important physiological parameters for physiologically-based pharmacokinetics models and thus, establish a solid foundation for future development of personalized medicines.

The liver is the main site of metabolic clearance in humans and is most often the focus of drug optimization and safety studies¹. The cytochrome P450 (CYP) superfamily consists of 57 genes and constitutes the major enzyme system responsible for the metabolism of a diverse array of endogenous and exogenous compounds^{2,3}. As a kind of membrane bound enzymes in eukaryotic cells, most of the CYPs, particularly those involved in the metabolism of drugs and xenobiotics, are located on the cytoplasmic side of the endoplasmic reticulum. With the development of tissue homogenate techniques and differential centrifugation methods, microsomal vesicles derived from the endoplasmic reticulum could be separated and subsequent evaluation of CYP enzymes showed their localization to microsomes⁴⁻⁶. Because of their reproducible nature, capacity for long-term storage, and extensive characterization of optimal incubation conditions, human liver microsomes (HLM) have become the dominant system used to characterize drug metabolism *in vitro*.

The amount of microsomal protein per gram of liver (MPPGL) is a critical scaling factor used in physiologically-based pharmacokinetics (PBPK) models to extrapolate *in vitro* rates of metabolism to drug clearance *in vivo*⁷⁻⁹. In order to assure the accuracy of predicted values for *in vivo* clearance, the MPPGL level should be determined precisely and individual variations in MPPGL should be considered. Unfortunately, to date there are only a limited number of studies concerning MPPGL amounts in human samples. Early estimates of MPPGL were limited because they were generated either from unmatched homogenate and microsomal samples¹⁰, or mean values of CYP content or cytochrome P450 oxidoreductase (POR) activity in homogenates and microsomes¹¹. Several studies also used only a small number of

Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.Q.(email: qiaohl@zzu.edu.cn)

livers^{12–16} and the background information for the samples was often incomplete. Moreover, the values for MPPGL reported by different groups used different tissue sources, different correction methods to account for losses of microsomal protein and relatively small sample sizes that in turn provided varying mean values¹⁶. These studies also did not give significant attention to the potential effects of individual variations in the MPPGL. Therefore, determination of the contents and individual variations in MPPGL over a large number of samples is needed in order to provide reliable physiological parameters for *in vivo* and *in vitro* research.

Traditionally, the *in vitro* metabolic activity of CYP is determined on the basis of per mg of microsomal protein (V_M), not on per gram of liver (V_L). However, the ultimate application of the *in vitro* metabolic study is within human tissue, the ability to obtain close estimates of *in vivo* behavior from the *in vitro* data is an important opportunity to be fully exploited. Though MPPGL were determined in relatively small size of liver tissues, considerable individual variations were found in MPPGL contents^{15,17}. Compared with CYP activity based on liver tissue, V_M has obvious disadvantage for the individual variation of activity might be underestimated, because the ignored MPPGL has larger individual variations. Consequently, the V_L could be more appropriate to represent the *in vitro* metabolism of CYP and to assess the individual variation in CYP activities.

Given the potential for large individual variations in response to a given drug dose, substantial effort and expense may be expended during drug development, particularly for drugs that have narrow therapeutic windows, which can frequently cause severe toxicities and even death. If the safe therapeutic range of a given drug in a population can be predicted before initiating a clinical trial, the efficiency of drug development would be improved. The *in vitro-in vivo* extrapolation (IVIVE) method affords researchers the opportunity to produce quantitative data on drug metabolism prior to studying pharmacokinetics *in vivo*. Therefore, after the first demonstration of IVIVE in rats in 1977¹⁸, many subsequent efforts were concentrated on this area. However, in these early studies there was a significantly predictive bias for *in vivo* clearance from the *in vitro* metabolic data because existing variation was not considered and instead mean parameter value reconstructed from very small data sets were used^{19–23}. Hence, further efforts were made to incorporate population variability into PBPK models to predict *in vivo* clearance^{24–26}.

Recently, the PBPK program in the Division of Pharmacometrics at the FDA decided to bring PBPK models into the drug review process (<http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm365118.htm>). However, valid predictions for *in vivo* clearance that are based on PBPK models require large numbers of different individual parameters. Although many individual characteristics can influence the outcomes of these predictions, the greatest attention has been given to variations that occur in drug metabolism, particularly that mediated by the liver²⁶. The five most important parameters in predicting hepatic clearances (CL_H) are: i) MPPGL, ii) *in vitro* metabolic clearance ($CL_{int, in vitro}$), iii) liver weight (LW), iv) hepatic blood flow (Q_H) and v) body weight (BW). Unfortunately, until now there have been no reports that used individual values for these important liver sample parameters to predict variations in *in vivo* clearance.

In order to assess the utility of individual parameters in predicting *in vivo* clearance rates, we assessed the metabolism of the sulfonylurea drug tolbutamide in liver samples. Tolbutamide is the probe of CYP2C9, which is one of the most abundant CYPs in human liver and is responsible for the metabolism of many drugs³. While the effects of genetic polymorphisms on CYP2C9 activities have been widely reported, experimental information demonstrating individual variations in tolbutamide metabolism *in vitro* are rather limited. An analysis of tolbutamide metabolism in HLM can be used not only to assess individual variations, but also to predict *in vivo* clearance rates. Such data will be informative for the design of personalized medicines.

In this study, 128 liver samples were collected to characterize individual variations in the contents of MPPGL and the metabolic activities of 10 CYPs based on microsomes (V_M) and liver tissues (V_L). For the first time, the distribution of MPPGL was assessed. The differences between V_M and V_L were compared and the correlations among V_M or V_L were analyzed. Furthermore, individual variations in the *in vivo* clearance of tolbutamide, used as a CYP2C9 probe substrate, were predicted using five important individual parameter values in large number of liver samples.

Results

Microsomal protein. *Individual variation in contents.* The values for MPPGL levels in 128 samples indicated a not-normal distribution, with minimal and maximal values of 6.71 and 127.95 mg microsomal protein per gram liver, representing a 19-fold variation (Fig. 1). The mean MPPGL content \pm SD was about 39.46 ± 21.57 mg/g liver. The values of MPPGL at the 2.5th and the 97.5th percentiles were 10.5 and 102.82 mg/g liver, respectively, exhibiting about a 10-fold variation. There was one extreme value (127.95 mg/g liver) and four outliers (116.50, 104.23, 97.98 and 96.97 mg/g liver) in MPPGL content. Compared with the other samples analyzed, these samples showed no extraordinary characteristics, so it can be inferred that individuals with extreme values of MPPGL do indeed exist in the population.

Effect of demographic factors and clinical data on contents. MPPGL content data were stratified by liver donor age, gender, smoking habit, alcohol consumption and tissue resource and then analyzed by Mann-Whitney U test or Kruskal-Wallis test. As shown in Table 1, MPPGL contents were not associated with either age ($P > 0.05$) or gender ($P > 0.05$). Smoking and alcohol consumption had no effects on




Figure 1. Frequency distribution of microsomal protein per gram of liver in 128 human livers.

Variables	Group	Number	Percentage (%)	MPPGL content (mg/g) (Mean \pm SD)
Gender	Male	40	31.3	41.50 \pm 21.21
	Female	88	68.8	38.53 \pm 21.79
Age (years)	20–45	51	39.8	37.71 \pm 21.31
	46–60	63	49.2	40.59 \pm 22.06
	61–75	14	10.9	40.69 \pm 21.45
Smoking	Non-smoking	115	89.8	39.10 \pm 21.86
	Smoking	13	10.2	42.58 \pm 19.30
Drinking	Non-drinking	115	89.8	39.13 \pm 21.93
	Drinking	13	10.2	42.36 \pm 18.64
Medical diagnosis	Hepatic cavernous hemangioma	93	72.7	38.25 \pm 21.93
	Metastatic carcinoma	10	7.8	40.79 \pm 19.07
	Cholelithiasis	9	7.0	41.03 \pm 28.73
	Gallbladder cancer	5	3.9	50.91 \pm 21.95
	Hepatic cholangiocarcinoma	7	5.5	45.42 \pm 15.45
	Hepatocellular carcinoma	4	3.1	35.99 \pm 12.68

Table 1. Donor characteristics of human liver samples and MPPGL content in donor subgroups (n = 128).

MPPGL values ($P > 0.05$). We failed to detect marked disease-related differences in MPPGL contents ($P > 0.05$).

The individual variation in metabolic activities of the CYP enzymes. *The metabolic activities based on microsomes.* Metabolic rates of 10 kinds of CYPs were detected in 78 liver microsomes using probe drugs known to be specific for each enzyme. The data of CYP activities shown in Table 2 and Fig. 2 demonstrated huge individual variations. The two biggest individual variations in V_M took place in the activity of CYP2C19 and CYP2A6, reaching to 232 and 109-fold, followed by that of CYP3A4/5 CYP2D6, CYP2C8, CYP2B6, CYP1A2 and CYP2E1, demonstrating the fold-change of 72, 45, 31, 24, 24, and 11, respectively (Fig. 2a). Compared with other CYP members, fold-change of CYP2C9 V_M was much lower but still achieving 6-fold. As shown in Fig. 2b, the highest variation (57-fold) in V_M at 95% PI existed in the activity of CYP2A6, whereas the remaining enzymes had the following rank order: CYP2C19 > CYP2D6 > CYP2C8 > CYP3A4/5 > CYP2B6 > CYP1A2 > CYP2E1 > CYP2C9 (28, 21, 17, 17, 12, 8, 5, and 5-fold, respectively).

The metabolic activities based on liver tissues. According to the contents of MPPGL determined above, individual metabolic rates per gram liver (V_M) were obtained by multiplying the individual MPPGL values, representing the CYP activity of liver tissue (Table 2). However, when calculation of CYP activity based on liver tissue, the individual variations of CYP activities were even more pronounced (Fig. 2a). V_L of CYP2A6 exhibited the largest individual variation (210-fold), followed by that of CYP2C19, showing

	Probe drug (Metabolite)		V_M (pmol/min/mg protein)	V_L (nmol/min/g liver)
CYP1A2	phenacetin (paracetamol)	Median	677.94	22.12
		Range	97.37–2368.14	3.16–119.91
		95% PI	169.20–1344.69	4.77–71.38
CYP2A6	coumarin (7-OH-coumarin)	Median	267.92	8.19
		Range	7.20–788.56	0.22–47.08
		95% PI	12.19–689.73	0.35–42.83
CYP2B6	bupropion (4-OH-bupropion).	Median	46.67	1.68
		Range	11.75–290.89	0.28–17.63
		95% PI	12.16–151.14	0.31–11.31
CYP2C8	paclitaxel (6-OH- Paclitaxel)	Median	31.50	0.96
		Range	2.74–87.23	0.12–7.71
		95% PI	4.34–74.27	0.17–4.81
CYP2C9	tolbutamide.(4-OH-tolbutamide)	Median	222.70	7.29
		Range	70.00–461.07	1.51–37.61
		95% PI	76.17–391.49	1.96–34.92
CYP2C19	omeprazole (4-OH-omeprazole)	Median	97.62	3.64
		Range	1.40–325.03	0.14–19.58
		95% PI	9.98–274.83	0.51–17.62
CYP2D6	dextromethorphan (3-methoxymorphinan)	Median	68.16	2.11
		Range	4.93–222.34	0.19–14.49
		95% PI	9.06–190.03	0.30–14.15
CYP2E1	chlorzoxazone (6-OH-chlorzoxazone)	Median	486.92	16.03
		Range	140.81–1604.44	3.28–74.52
		95% PI	198.24–1061.97	4.60–69.28
CYP3A4/5	midazolam (1-OH-midazolam)	Median	836.56	29.05
		Range	57.24–4144.93	2.93–251.26
		95% PI	178.15–2967.83	3.55–217.79

Table 2. Metabolic activities of the individual CYP enzymes in human livers (n = 78). V_M : metabolic rate of the individual CYP enzyme based on per mg microsomal protein; V_L : metabolic rate of the individual CYP enzyme based on per gram liver tissue; PI: percentile interval.




Figure 2. Fold-change of CYP metabolic activity based on microsomes (V_M) or liver tissues (V_L). The individual fold-change is expressed as the ratio between the maximal and minimal values of CYP metabolic rate (a) or between the 97.5th and the 2.5th percentiles of the observed CYP metabolic rate (b).




Figure 3. Percentage of rank change of individual V_L compared with corresponding V_M in 10 CYPs of 78 liver samples. 78 samples were ranked in ascending order according to the value of V_M or V_L for each CYP isoform, respectively. The rank change for each CYP isoform of each individual was the absolute difference value between the rank of V_M and the rank of corresponding V_L . The percentage of rank change was calculated by the total samples of 78 divided by rank change absolute value of each individual and every change of 10% as a group (such as 0%–10%, 10%–20%). The percentage of the samples in each group to total samples was also calculated. Rank change of less than 10% was considered as tiny change, between 10% and 20% as moderate change, between 20% and 50% as obvious change and exceeding 50% as dramatic change.

144-fold individual variation. The remaining enzymes had the following rank order: CYP3A4/5 > CYP2D6 > CYP2B6 > CYP2C8 > CYP1A2 > CYP2C9 > CYP2E1 (86, 77, 64, 63, 38, 25 and 23-fold, respectively). The biggest individual variation in V_L at 95%PI took place in the activity of CYP2A6, reaching to 122, followed by CYP3A4/5, CYP2D6, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2E1, and CYP1A2, demonstrating the fold-change of 61, 46, 36, 34, 28, 18, 15 and 15, respectively (Fig. 2b).

The inter-individual variations in V_M and V_L . As shown in Fig.2a, inter-individual variations in the V_L of CYPs were much higher than those of corresponding V_M except CYP2C19. The fold-changes in V_L of CYP2C9, CYP2B6, CYP2E1, CYP2C8, CYP2A6, CYP2D6, CYP1A2 and CYP3A4/5 exceeded those of corresponding CYP V_M by 278%, 159%, 99%, 96%, 92%, 71%, 56% and 18%, respectively. However, the fold-change in V_L of 2C19 decreased by 38% compared with that of CYP2C19 V_M . When the fold-change expressed as ratio between 95% PI of the observed CYP metabolic activities (Fig. 2b), the inter-individual variation degree of V_L in all the CYP isoforms were higher than the corresponding V_M . Among 10 CYPs, V_L of CYP2C9, CYP2B6, CYP2E1, CYP2C8, and CYP2A6 had the large amplitude of variation whereas those for CYP3A4/5 and CYP2C19 were less compared with corresponding V_M (Fig. 2b). Additionally, in our study the metabolic rates of CYP2C19 and CYP2A6 showed the highest fold-changes of the measured enzymes; whereas those for CYP2C9, CYP1A2 and CYP2E1 were relatively lower (Fig. 2).

The intra-individual variations between V_M and V_L . The inter-individual variations of CYP metabolic activities in V_M and V_L were shown in Table 2 and Fig. 2. However, the intra-individual variation between V_L and the corresponding V_M in each CYP isoform of 78 samples was unknown and this situation was described by rank change percentage (Fig. 3). Rank change of individual V_L compared with corresponding V_M in 10 CYPs was obvious. For CYP1A2, CYP2C8, CYP2C9 and CYP2E1, the place change exceeding 20% accounted for 47%, 41%, 40% and 41% of the total samples, respectively, whereas those for the remaining CYPs were about 30%. Owing to the extremely high or low MPPGL amounts in some individuals, rank changes of certain CYP isoforms in these cases varied drastically. As shown in Fig. 3, the rank change of CYP2E1 in one sample experienced the most dramatic change, up 54 places (change of 69%). Next were CYP1A2 (2 cases), CYP2B6 (1 case), CYP2C9 (6 cases), CYP3A4 (1 case), CYP2C8 (2 cases), CYP2C19 (1 case), altering 41–51 places (change of 51–65%).

Effects of demographic factors and clinical data on CYP activities. Univariate analysis was performed to investigate whether demographic factors were associated with V_M and V_L (Fig. 4). There were no statistically significant differences ($P > 0.05$) in the metabolic activities of ten CYPs as a function of gender, age, smoking status, drinking habit or tissue resources with three exceptions. Statistically significant differences between V_M of CYP1A2 in male and female donors ($P = 0.003$, $n = 78$) were seen, which was consistent with other studies^{27,28}. Comparing with age 3 group (61–75 years old), the V_M of CYP2C8 and CYP2C9




Figure 4. Influences of demographic factors on CYP activities. Effects of sex on the metabolic activity of CYP1A2 (a), effects of age on the metabolic activity of CYP2C8 (b) and CYP2C9 (c) in liver microsomes. Data are shown as box plots representing medians with minimal and maximal values.

were significantly higher in age 1 (20–45 years old) and age 2 (46–60 years old) groups (Fig. 4b, c). Yang *et al.*²⁹ also found age had a substantial impact on the activity of CYP2C9.

Association between MPPGL contents and CYP activities. Association based on microsomes. Spearman correlation analysis was used to identify the correlations between MPPGL contents and V_M for 10 CYP, respectively, and the results showed there was no significant correlation between MPPGL contents and V_M of 10 CYPs ($P > 0.05$) (Supplementary Fig. S1).

Association based on liver tissues. In contrast to V_M , there were strong correlations ($r \geq 0.6$, $P < 0.001$) between MPPGL contents and V_L of CYPs besides CYP2A6, CYP3A4/5, CYP2C8 (moderate correlations, $0.3 \leq r < 0.6$, $P < 0.001$) (Supplementary Fig. S2).

Prediction of tolbutamide hepatic clearance. *In vitro* clearance of tolbutamide. The mean \pm SD of the V_{max} and K_m for tolbutamide 4-hydroxylation was 255.82 ± 79.48 (range 83.76 to 454.80) pmol/mg/min and 235.73 ± 99.78 (range 101.20 to 531.90) μ M, respectively. Both the V_{max} and K_m values displayed individual variations of 5-fold, with the variations at 95% percentiles interval (PI) still reaching to 5-fold. The values of $CL_{int, in vitro}$ for 4-OH-tolbutamide by CYP2C9 are shown in Supplementary Table S1 and the not-normal distribution of the values displayed a 21-fold individual variation between the highest and lowest values.

All parameters used to predict the hepatic clearance of tolbutamide in the 78 HLM samples are listed in Supplementary Table S1. The variable degrees of the other three parameters were relatively lower, with only BW variations reaching 2-fold.

Prediction of tolbutamide hepatic clearance. The predicted and observed CL_H for tolbutamide are shown in Table 3. The mean values for the predicted CL_H of tolbutamide obtained by seven methods were all 0.113 ml/min/kg, but the predicted ranges showed obvious variations. Method G gave merely the mean value, whereas method A predicted the largest individual variation (51-fold between the highest and lowest values). Even at the 95% PI, the predicted variation still reached 30-fold with method A. Using only individual MPPGL or $CL_{int, in vitro}$ values, method B and C also displayed large individual variations (about 13- and 20-fold, respectively). In contrast, the ranges of the predicted CL_H for tolbutamide were relatively narrow as calculated with method D, E and F, with less than 2-fold variation between the minimal and maximal values. The effects of individual values for the five parameters on the predicted CL_H for tolbutamide are presented in Supplementary Fig. S3. Together these results indicate that ignoring individual variations in parameter values would lead to a failure to identify individuals who fall at the extremes of the population.

Prediction accuracy. As shown in Table 4, the mean average fold-error (AFE) values calculated by all of the seven methods (A-G) were the same (0.58), but the variable degrees of AFE were quite different. Method G gave merely the mean value, whereas method A predicted the largest individual variation in AFE (50-fold between the highest and lowest values). Even at the 95% PI, the predicted variation still reached 30-fold with method A. Using only individual MPPGL or $CL_{int, in vitro}$ values, method B and C also displayed large individual variation in AFE (about 13- and 20-fold, respectively). In contrast, the ranges in AFE values yielded by methods D, E and F were relatively narrow, with less than 2-fold variation between the minimal and maximal values. The percentage of predictions that fell within 2-fold of the *in vivo* value were different between different methods. By not incorporating the individual variation of these five parameters, or using the less variable degree in individual Q_H and LW, methods G, E and D provided overall accuracy. However, owing to the large individual variations seen for MPPGL and

	n	Range	Fold change (Max/Min)	Mean \pm SD	95% PI	Fold change (95% PI)
Predicted CL _H (ml/min/kg)						
Method A	78	0.011–0.559	50.8	0.113 \pm 0.095	0.012–0.365	30.4
Method B	78	0.027–0.341	12.6	0.113 \pm 0.065	0.038–0.311	8.2
Method C	78	0.018–0.353	19.6	0.113 \pm 0.064	0.026–0.268	10.3
Method D	78	0.093–0.142	1.5	0.113 \pm 0.011	0.095–0.139	1.5
Method E	78	0.1128–0.1130	1.0	0.113 \pm 0.000	0.1128–0.1130	1.0
Method F	78	0.079–0.161	2.0	0.116 \pm 0.019	0.082–0.155	1.9
Method G	78	—	—	0.113	—	—
Observed CL _H (ml/min/kg)						
Back <i>et al.</i> ⁴⁷	7			0.260 \pm 0.100		
Back <i>et al.</i> ⁴⁷	6			0.226 \pm 0.024		
Back <i>et al.</i> ⁴⁷	6			0.239 \pm 0.050		
Miners <i>et al.</i> ⁴⁸	6			0.171 ^a		
Wilner <i>et al.</i> ⁴⁹	6			0.147 \pm 0.013		
Wing <i>et al.</i> ⁵⁰	7			0.159 ^a		

Table 3. Values for hepatic clearance of tolbutamide 4-hydroxylation and their variations. Method A used the individual values for each parameter (MPPGL, CL_{int, in vitro}, LW, Q_H and BW) for 78 livers. Method B used the individual MPPGL value and the mean values for the remaining four parameters. Similar to method B, method C, D, E and F used the individual CL_{int, in vitro}, LW, Q_H or BW value, respectively, and the mean values for the remaining four parameters. Method G used the mean value of the five parameters for that particular liver. ^aNo SD is available. PI: percentile interval.

Method	AFE			
	Mean \pm SD	Range	95% PI	% within of 2-fold error
A	0.58 \pm 0.48	0.057–2.86	0.062–1.86	42
B	0.58 \pm 0.33	0.14–1.74	0.20–1.59	46
C	0.58 \pm 0.33	0.09–1.80	0.13–1.37	54
D	0.58 \pm 0.06	0.47–0.72	0.48–0.71	92
E	0.58 \pm 0.00	0.577–0.578	0.5767–0.5776	100
F	0.59 \pm 0.10	0.40–0.82	0.42–0.79	82
G	0.58	—	—	100

Table 4. Comparing the accuracy of predictions using different methods. AFE (average fold-error) was used to assess the accuracy of predictions while a two-fold precision limit corresponds to 0.5–2 of AFE values. Method A used individual values for each parameter (MPPGL, CL_{int, in vitro}, LW, Q_H and BW) for 78 livers. Method B considered the individual MPPGL value and the mean values for the remaining four parameters. Similar to method B, methods C, D, E and F used the individual CL_{int, in vitro}, LW, Q_H or BW value, respectively, and the mean value for the remaining four parameters. Method G used mean values for the five parameters for that particular liver. PI: percentile interval.

CL_{int, in vitro} values, only 42%, 46% and 52% of the samples were within the 2-fold error as determined by method A, B and C, respectively.

Discussion

This is the first extensive study to investigate the distribution of microsomal protein contents in a large number of normal liver samples. The not-normally distributed MPPGL values in 128 samples varied from 6.71 to 127.95 mg/g liver and the range at 95% PI were 10.5 to 102.82 mg/g. Meanwhile, the metabolic activities of 10 CYPs were detected in microsomes and liver tissues, respectively, which showed huge individual variations and the variation for some CYPs could reach over 200-fold. Compared with microsomes, the activities of liver tissues were much suitable to express the individual variations of CYP activities. Furthermore, individual variations in *in vivo* clearance of tolbutamide were successfully

predicted with the individual parameter values and we provided a valuable database of metabolic parameters for normal livers for use in PBPK modeling.

Previous studies demonstrated that the CYP content and POR activity used for correcting the loss of MPPGL in homogenates are all essentially microsomal in origin³⁰, and the corrected values of MPPGL based on either CYP contents or POR activities are comparable and not significantly different^{15,16}. The average MPPGL value of 39.46 mg/g based on the POR activity from 128 liver tissues was essentially the same as the value obtained for 38 liver samples (40 mg/g¹⁶) and is in good agreement with the result of Pelkonen *et al.* (36 mg/g¹¹). Thus, there is general agreement between various laboratories using a variety of methodologies. While our mean_{geo} value of MPPGL is greater than the mean_{geo} value of 28 mg/g determined by Barter *et al.*¹⁷, it is noteworthy that this result came from unpublished data and thus detailed information for the donors was not available. In addition, two other studies reported higher average MPPGL levels, in which the value of 77 mg/g was obtained from only four liver tissue samples¹² and the determination of 53 mg/g was achieved by ELISA¹⁴. The use of ELISA to correct for microsomal losses is not a common approach, and this disparity may be due to differences in the correction methods used in these studies (i.e., POR activity vs. ELISA). In a previous study by this group a mean MPPGL value of 20 mg/g¹³ was obtained by using glucose-6-phosphatase activity to correct for microsomal loss.

To date only limited laboratory measurements concerning the variations in the contents of MPPGL were available and the largest reported variation was approximately 6-fold¹⁷. However, in the present study up to a 19-fold variation was detected and even at the 95% PI there was still a 10-fold variation, which is much higher than that reported in the literature. It should be emphasized that the present study used a larger number of samples and the range of MPPGL values obtained here overlapped with the results reported by other investigators^{16,17}. The determination of MPPGL is time-consuming and requires the coordination of several operators. To ensure the accuracy of the MPPGL results, the effect of inter-operator differences on MPPGL values was investigated. Pooled human livers (n = 5) were respectively assessed by three operators in triplicate and the results showed that the difference in the MPPGL values obtained by different operators was not substantial and was less than 20%, which is in good agreement with a study by Wilson *et al.*³¹. As such, the large variation in the MPPGL levels seen in our study most likely represents the true biological variability present in the population. Taken together, our study offers physiological values for MPPGL in normal liver samples that have clear background information.

In general, the *in vitro* activity of CYP is based on microsomes (V_M) and a number of studies have reported the high degrees of individual variations in the V_M (such as 30-, 45-, 405-, 1790-, 30- and 124-fold for CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP2E1 and CYP3A4^{28,32–35}, respectively). Our study also found large individual variations in V_M (Table 2 and Fig. 2). However, as the actual contents of MPPGL are unusually unknown, so far no reports are available regarding the metabolic activities of CYP on the basis of per gram liver (V_L). Since the determination of MPPGL amount in our study, it has been found that the individual variations of CYP V_L were much higher than those of corresponding V_M . As shown in Fig. 2, the degree of the overall variation of V_L for CYP2C9, CYP2B6, CYP2E1, CYP2C8 and CYP2A6 increased substantially comparing with those of corresponding V_M of CYPs. Meanwhile, the intra-individual variation between V_L and the corresponding V_M in each CYP isoform of 78 samples was large. Especially for CYP1A2, CYP2C8, CYP2C9 and CYP2E1, more than 40% of the samples changed more than 20% of the total rank and for some cases, the rank change over more than 60% (Fig. 3). The reason for large rank change is due to the variation in MPPGL, especially the effect of extreme values in MPPGL. For example, the highest MPPGL contents in some cases resulted in the huge increase of rank whereas the lowest led to the dramatic decrease of rank. The change of the rank for each individual between V_M and the corresponding V_L indicated that V_M didn't equal to V_L especially for the individuals with drastic rank changes. Taken together, it can be concluded that V_L is preferred over the V_M in representing the individual variations of CYP metabolic activity for the latter may mask the real individual variations of enzyme activities.

There are four stages in the IVIVE strategy, in which MPPGL, $CL_{int, in vitro}$, LW , Q_H and BW are necessary parameters⁹. These parameters thus play a vital role in the accurate prediction of *in vivo* clearance rates. However, to our knowledge the various values for these important parameters used in the IVIVE were only single mean values^{7,36} and no consideration was given to variations in these parameters. Here, for the first time the individual values for the five of parameters were used to predict individual variations in hepatic tolbutamide clearance in a large number of liver samples. As shown in Table 3 and Supplementary Fig. S3, seven methods were designed to predict the hepatic clearance of tolbutamide. Because the mean and individual values of the five parameters used with the seven methods came from the same population, the mean values of the tolbutamide CL_H predicted by each of the methods were the same. However, the variable degrees of the predicted CL_H were quite different. Method G, which is a rather traditional “point” to “point” predictive manner, only provided the mean value and thus could not offer information on variations in the population. Method A, as a new approach that was used in this study, incorporated the individual variations of the five parameters into the prediction and in turn displayed as much as a 51-fold individual variation in the distribution of the predicted CL_H for tolbutamide. Thus, the ability to predict individual variations in CL_H is superior to the estimate of a mere mean. For future drug research and development, the prediction of the CL_H range in the human body prior to the initiation of clinical studies can provide information about the effective range and toxic doses that can improve the efficiency of research on novel therapeutics. For older drugs that are currently in clinical

use and have large individual variations, method A can help to re-assess the safety of these drugs and to provide a firm basis for the design of personalized treatments.

In contrast, methods B-F evaluated the effect of individual variation of a single parameter (MPPGL, $CL_{int, in vitro}$, LW , Q_H or BW) on the prediction. Each parameter could affect the individual variation of the predicted CL_H , but the contributions of the five parameters were different. The large individual variation predicted by method A was mainly caused by the variation in MPPGL and $CL_{int, in vitro}$, so MPPGL and $CL_{int, in vitro}$ thus could play essential roles in the process of IVIVE. Among all the parameters used in IVIVE, individual values for MPPGL and $CL_{int, in vitro}$ were not easily obtained, therefore prediction of the individual variation in CL_H would be highly difficult. In this study, individual values for the five kinds of important parameters were determined and used to predict the CL_H of tolbutamide.

In order to assess the accuracy of the predictions, a comparison of the predicted hepatic clearance with the *in vivo* clearance in humans is needed. Due to a lack of human intravenous pharmacokinetic data in the Chinese population, data suitable for assessment of tolbutamide CL_H predictions in Caucasian populations were selected from four previous studies (Table 3). As was previously known, CYP2C9 is highly polymorphic and the frequencies of CYP2C9*2 and CYP2C9*3, which exhibit poor enzymatic activity compared to CYP2C9*1³⁷, were higher in Caucasians compared to that in Chinese populations. Therefore, a reasonable assumption could be made that the metabolic activity of CYP2C9 should differ between Caucasian and Chinese populations. However, the $CL_{int, in vitro}$ of tolbutamide in Caucasian population (mean \pm SD, range: 1.0 ± 0.2 , $0.5-2.5$; 1.35 ± 1.23 , $0.27-4.0 \mu\text{l}/\text{mg}/\text{min}$) were reported by McGinnity *et al.*³⁸ and Carlile *et al.*³⁹, respectively, which were in good agreement with those of Chinese people (mean \pm SD, range: 1.32 ± 0.75 , $0.20-4.18 \mu\text{l}/\text{mg}/\text{min}$, this study). The consistency of the $CL_{int, in vitro}$ of tolbutamide in these two ethnic groups might suggest that gene polymorphisms in CYP2C9 have little effect on the metabolism of tolbutamide in ethnic Chinese and Caucasians. Consequently, the *in vivo* CL_H for tolbutamide derived from the Western population should be suitable for comparisons with the predicted CL_H for tolbutamide in Chinese patients. The predicted mean value within 2-fold of actual values showed that each of the methods was accurate in predicting the CL_H of tolbutamide (Table 4).

However, more than half of the samples fell outside of the 2-fold error for method A, B and C, which may explain, at least in part, the bias that exists in most IVIVE studies. Traditionally, IVIVE employed only mean values to make predictions and as such cannot provide a range of AFE. In fact, as observed in our study, large variations indeed exist in many drug metabolism steps, so a method that incorporates into the IVIVE individual variations in each step can be a suitable way to make accurate predictions for *in vivo* CL_H .

In conclusion, MPPGL values were determined and considerable individual variations in the contents were found in Chinese population. The metabolic activity of CYP based on liver tissue is a new method to assess the *in vitro* metabolic activity of CYP and superior to the metabolic activity of CYP based on microsomes. For the first time the individual values of five different parameters were used to predict individual variations in hepatic clearance in a large number of liver samples and variations in the *in vivo* clearance rates of tolbutamide were successfully predicted. These findings provide important physiological parameters for PBPK and furthermore, build a solid foundation for future development of personalized medicines.

Methods

Materials and Chemicals. All probe drugs and part metabolites used in this work were purchased from the National Institute for the Food and Drug Control (China), including phenacetin, coumarin, bupropion, paclitaxel, tolbutamide, omeprazole, dextromethorphan, chlorzoxazone, midazolam and paracetamol (phenacetin metabolite). Other metabolites (7-OH-coumarin, 4-OH-bupropion, 6-OH-Paclitaxel, 4-OH-tolbutamide, 4-OH-omeprazole, 3-methoxymorphinan, 6-OH-chlorzoxazone and 1-OH-midazolam) were obtained from Toronto Research Chemicals, Inc. (Canada). Methanol and acetonitrile were HPLC grade and were purchased from Siyou Chemical Reagent Co. (China). Reduced nicotinamide adenine dinucleotide phosphate (NADPH) and horse cytochrome C were obtained from Solarbio Science and Technology co. (China).

Human liver samples. One hundred and twenty-three Chinese liver tissues were previously collected⁴⁰ from patients undergoing liver surgery during 2012 and 2014 in the first affiliated hospital of Zhengzhou University, the People's Hospital of Henan Province, and the Tumors' Hospital of Henan Province, respectively, besides 5 newly collected samples. The study was approved by the ethics committees of Zhengzhou University and written informed consent was obtained from each patient. All experiments were performed in accordance with the approved guidelines of Zhengzhou University ethics committees. Detailed information for each patient was well-documented and included gender, age, body height, body weight, smoking habits, alcohol consumption, clinical diagnosis, regular drug intake before surgery, previous history, allergic history, pathological diagnosis, imaging examination and laboratory test data (including, but not limited to, results from routine blood analysis, liver function tests and renal function tests). Liver samples from tumorous patients were 2 cm distant from the tumor tissues. Samples from normal livers were collected, with liver health confirmed by liver function tests, histopathological

analysis and imaging examination by ultrasonography or CT. All liver samples were frozen immediately after removal and stored in liquid nitrogen until use.

Preparation of liver microsomes. Tissue samples were thawed on ice and weighed. The samples were finely homogenized on ice using a glass homogenizer in 0.05 M Tris-HCl (pH 7.0) buffer containing 1.12% w/v KCl and 1.12% v/v EDTA (10 ml per gram liver). After mixing, 0.5 ml of the homogenate was retained for POR activity analysis while the remaining sample was centrifuged at $9,000 \times g$ for 20 min at 4 °C. The supernatant was collected and centrifuged at $100,000 \times g$ for 1 hour at 4 °C with a Beckman Optima L-100K ultracentrifuge. The resulting microsomal pellet was resuspended in 0.15 M Tris-HCl (pH 7.6) buffer and centrifuged for an additional hour at $100,000 \times g$ at 4 °C. The final microsome pellet was suspended in 0.25 M sucrose (2 ml per gram original sample). Both the homogenate and microsomal suspension were frozen in liquid nitrogen and stored at -80°C until analysis. Microsomal protein concentrations were determined according to the Bradford method.

Determination of microsomal protein per gram of liver (MPPGL) levels. The activity of POR as measured in homogenates and microsomes produced from the same liver tissue sample was used to estimate the amount of MPPGL⁴¹. The POR assay is based on the rate of cytochrome C reduction by liver microsomes⁴². The reaction was conducted in 200 μl solution with 0.3 M potassium phosphate buffer (pH 7.7), 0.2 mM horse cytochrome C, and 5 μg microsomal proteins. Reactions were initiated by the addition of 20 μl 10 mM NADPH to 200 μl assay mixture for a total volume of 220 μl . The rate of cytochrome C reduction was determined from the rate of increase in absorbance at 550 nm produced by the reduced form of cytochrome C using a BioTek Synergy H1MD Multi-Mode microplate reader in the kinetic mode before and after the addition of NADPH (0–5 min). MPPGL values were calculated with the following equation¹⁵: $\text{MPPGL} = \{\text{rate of reduction}_{\text{homogenate}} (\text{nM}/\text{min}/\text{g liver})\} / \{\text{rate of reduction}_{\text{microsome}} (\text{nM}/\text{min}/\text{mg microsomal protein})\}$.

Measurement of CYP metabolic activities. Marker activities selective for individual CYP isoforms were determined at single concentrations in individual assays by incubation of 0.2–0.5 mg microsomal protein, 1 mM NADPH and the respective substrate (400 μM phenacetin for CYP1A2, 20 μM coumarin for CYP2A6, 500 μM bupropion for CYP2B6, 40 μM paclitaxel for CYP2C8, 1500 μM tolbutamide for CYP2C9, 250 μM omeprazole for CYP2C19, 320 μM dextromethorphan for CYP2D6, 500 μM chlorzoxazone for CYP2E1 and 50 μM midazolam for CYP3A4/5). In addition, seven different concentrations of tolbutamide (31.25 to 2000 μM) were examined to determine the V_{max} and K_{m} of 4-OH-tolbutamide and the *in vitro* CL_{int} of tolbutamide was calculated using the following equation: $\text{CL}_{\text{int in vitro}} = V_{\text{max}}/K_{\text{m}}$. Incubation conditions were ensured linear metabolite formation with respect to reaction time and protein concentration. Each reaction was terminated after specified incubation period by adding 20 μl ice-cold acetonitrile or 1 ml ethyl acetate or perchloric acid and metabolite concentrations were determined by HPLC-UV or HPLC-FLD.

Prediction of tolbutamide hepatic clearance. The $\text{CL}_{\text{int in vitro}}$ values obtained for tolbutamide were scaled to *in vivo* clearance by the following equations. The whole liver intrinsic clearance ($\text{CL}_{\text{int, liver}}$) was estimated as:

$$\text{CL}_{\text{int, liver}} = \text{CL}_{\text{int, in vitro}} \times \text{MPPGL} \times \text{LW}/\text{BW} \quad (1)$$

Where LW is liver weight and BW refers to body weight. According to the body weight given for each patient, the liver weight (LW) was calculated from the liver volume (LV) multiplied by liver density, where $\text{LV (ml)} = 12.5 \times \text{BW (kg)} + 536.4^{43}$ and liver density is 1.001 g/ml⁴⁴. The formula for liver volume was derived from data collected from a Chinese population.

The hepatic clearance (CL_{H}) of tolbutamide hydroxylation was then predicted using the well-stirred model:

$$\text{CL}_{\text{H}} = (\text{Q}_{\text{H}} \times \text{CL}_{\text{int, liver}} \times \text{fub}) / (\text{Q}_{\text{H}} + \text{CL}_{\text{int, liver}} \times \text{fub}) \quad (2)$$

Where fub is fraction unbound in blood (0.0982)^{8,45} and Q_{H} is liver blood flow, which is often expressed as a percentage of cardiac output because of the difficulty in determining the Q_{H} . Q_{H} was assumed to be 24.5% of cardiac output⁷. The values for cardiac output originated from data for normal Han Chinese males ($n = 783$) and females ($n = 805$) and the mean values from each group were selected according to the age and gender of the donors in this study⁴⁶.

Both the mean and individual values for the five different parameters observed in this study (MPPGL, $\text{CL}_{\text{int, in vitro}}$, LW, Q_{H} and BW) were used to predict the hepatic clearance of tolbutamide. According to the different combinations of mean and individual values of the five parameters, seven methods were employed. Method A used individual values for each parameter for that particular liver ($n = 78$). Method B used the individual MPPGL value and the mean value of the remaining four parameters. Similar to method B, methods C, D, E and F used the individual $\text{CL}_{\text{int, in vitro}}$, LW, Q_{H} or BW value, respectively, and

the mean value of the remaining four parameters. Method G used the mean value of the five parameters for 78 livers.

Due to a scarcity of data for the Chinese population, observed intravenous clearance values for tolbutamide were obtained from *in vivo* studies performed with healthy Caucasian subjects.

The accuracy of the predictions was assessed from the average fold-error (AFE). A two-fold precision limit corresponds to 0.5–2 of AFE values, where $AFE = 10^{(\sum \log(\text{Predicted}/\text{Observed})/N)^{21}}$. N refers to the number of separate reports in the literature concerning tolbutamide intravenous clearance.

Statistical Analyses. The normality of the data distribution was assessed using the method of Kolmogorov-Smirnov and Shapiro-Wilk. Because most data sets were not normally distributed, non-parametric methods were generally used for statistical analyses. The Mann-Whitney *U* test was used for pairwise comparison and the Kruskal-Wallis *H* test was applied for multiple pairwise comparisons. Non-parametric Spearman rank correlation analysis was performed to calculate the correlation coefficient (*r*). A *P* value < 0.05 was considered statistically significant (two-tailed). SPSS statistics 17 software was used for data management and statistical analyses. Graphs were generated using GraphPad Prism software 5.04.

References

- Zhang, H., Davis, C. D., Sinz, M. W. & Rodrigues, A. D. Cytochrome P450 reaction-phenotyping: an industrial perspective. *Expert Opin Drug Metab Toxicol.* **3**, 667–687 (2007).
- Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther.* **138**, 103–141 (2013).
- Martiny, V. Y. & Miteva, M. A. Advances in molecular modeling of human cytochrome P450 polymorphism. *J Mol Biol.* **425**, 3978–3992 (2013).
- Ekins, S., Ring, B. J., Grace, J., McRobie-Belle, D. J. & Wrighton, S. A. Present and future *in vitro* approaches for drug metabolism. *J Pharmacol Toxicol Methods.* **44**, 313–324 (2000).
- Reed, J. R. & Backes, W. L. Formation of P450. P450 complexes and their effect on P450 function. *Pharmacol Ther.* **133**, 299–310 (2012).
- Fujiki, Y., Hubbard, A. L., Fowler, S. & Lazarow, P. B. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. *J Cell Biol.* **93**, 97–102 (1982).
- Barter, Z. E., Tucker, G. T. & Rowland-Yeo, K. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. *Clin Pharmacokinet.* **52**, 1085–1100 (2013).
- Poulin, P., Kenny, J. R., Hop, C. E. & Haddad, S. *In vitro-in vivo* extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. *J Pharm Sci.* **101**, 838–851 (2012).
- Houston, J. B. Utility of *in vitro* drug metabolism data in predicting *in vivo* metabolic clearance. *Biochem Pharmacol.* **47**, 1469–1479 (1994).
- Schoene, B., Fleischmann, R. A., Remmer, H. & von Oldershausen, H. F. Determination of drug metabolizing enzymes in needle biopsies of human liver. *Eur J Clin Pharmacol.* **4**, 65–73 (1972).
- Pelkonen, O., Kaltiala, E. H., Larmi, T. K. & Karki, N. T. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. *Clin Pharmacol Ther.* **14**, 840–846 (1973).
- Baarnhielm, C., Dahlback, H. & Skanberg, I. *In vivo* pharmacokinetics of felodipine predicted from *in vitro* studies in rat, dog and man. *Acta Pharmacol Toxicol (Copenh).* **59**, 113–122 (1986).
- Lipscomb, J. C. & Fisher, J. W., Confer, P.D. & Byczkowski, J.Z. *In vitro* to *in vivo* extrapolation for trichloroethylene metabolism in humans. *Toxicol Appl Pharmacol.* **152**, 376–387 (1998).
- Lipscomb, J. C., Teuschler, L. K., Swartout, J. C., Striley, C. A. & Snawder, J. E. Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver. *Toxicol Mech Methods.* **13**, 45–51 (2003).
- Wilson, Z. E. *et al.* Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. *Br J Clin Pharmacol.* **56**, 433–440 (2003).
- Hakooz, N. *et al.* Determination of a human hepatic microsomal scaling factor for predicting *in vivo* drug clearance. *Pharm Res.* **23**, 533–539 (2006).
- Barter, Z. E. *et al.* Scaling factors for the extrapolation of *in vivo* metabolic drug clearance from *in vitro* data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Curr Drug Metab.* **8**, 33–45 (2007).
- Rane, A., Wilkinson, G. R. & Shand, D. G. Prediction of hepatic extraction ratio from *in vitro* measurement of intrinsic clearance. *J Pharmacol Exp Ther.* **200**, 420–424 (1977).
- Iwatsubo, T. *et al.* Prediction of *in vivo* drug metabolism in the human liver from *in vitro* metabolism data. *Pharmacol Ther.* **73**, 147–171 (1997).
- Nestorov, I., Gueorguieva, I., Jones, H. M., Houston, B. & Rowland, M. Incorporating measures of variability and uncertainty into the prediction of *in vivo* hepatic clearance from *in vitro* data. *Drug Metab Dispos.* **30**, 276–282 (2002).
- Ito, K. & Houston, J. B. Prediction of human drug clearance from *in vitro* and preclinical data using physiologically based and empirical approaches. *Pharm Res.* **22**, 103–112 (2005).
- Riley, R. J., McGinnity, D. F. & Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from *in vitro* intrinsic clearance data in hepatocytes and microsomes. *Drug Metab Dispos.* **33**, 1304–1311 (2005).
- Hallifax, D., Foster, J. A. & Houston, J. B. Prediction of human metabolic clearance from *in vitro* systems: retrospective analysis and prospective view. *Pharm Res.* **27**, 2150–2161 (2010).
- Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T. & Rostami-Hodjegan, A. Prediction of *in vivo* drug clearance from *in vitro* data. I: impact of inter-individual variability. *Xenobiotica.* **36**, 473–497 (2006).
- Inoue, S. *et al.* Prediction of *in vivo* drug clearance from *in vitro* data. II: potential inter-ethnic differences. *Xenobiotica.* **36**, 499–513 (2006).
- Rostami-Hodjegan, A. & Tucker, G. T. Simulation and prediction of *in vivo* drug metabolism in human populations from *in vitro* data. *Nat Rev Drug Discov.* **6**, 140–148 (2007).
- Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther.* **270**, 414–423 (1994).

28. Yang, J. *et al.* Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. *Br J Clin Pharmacol.* **73**, 268–284 (2012).
29. Yang, X. *et al.* Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. *Genome Res.* **20**, 1020–1036 (2010).
30. Carlile, D. J., Zomorodi, K. & Houston, J. B. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. *Drug Metab Dispos.* **25**, 903–911 (1997).
31. Barter, Z. E. *et al.* Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. *Drug Metab Dispos.* **36**, 2405–2409 (2008).
32. He, P., Court, M. H., Greenblatt, D. J. & von Moltke, L. L. Factors influencing midazolam hydroxylation activity in human liver microsomes. *Drug Metab Dispos.* **34**, 1198–1207 (2006).
33. Mohri, T. *et al.* Human CYP2E1 is regulated by miR-378. *Biochem Pharmacol.* **79**, 1045–1052 (2010).
34. Wang, H. *et al.* Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. *Pharmacogenomics.* **12**, 481–492 (2011).
35. Yoshida, R. *et al.* Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity *in vivo* and *in vitro*. *Clin Pharmacol Ther.* **74**, 69–76 (2003).
36. Gill, K. L., Houston, J. B. & Galetin, A. Characterization of *in vitro* glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. *Drug Metab Dispos.* **40**, 825–835 (2012).
37. Dai, D. P. *et al.* *In vitro* functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. *Acta Pharmacol Sin.* **34**, 1449–1456 (2013).
38. McGinnity, D. F., Parker, A. J., Soars, M. & Riley, R. J. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. *Drug Metab Dispos.* **28**, 1327–1334 (2000).
39. Carlile, D. J., Hakooz, N., Bayliss, M. K. & Houston, J. B. Microsomal prediction of *in vivo* clearance of CYP2C9 substrates in humans. *Br J Clin Pharmacol.* **47**, 625–635 (1999).
40. Zhang, H. *et al.* Effect of Cytochrome b5 Content on the Activity of Polymorphic CYP1A2, 2B6, and 2E1 in Human Liver Microsomes. *PLoS One.* **10**, e0128547 (2015).
41. De Bock, L. *et al.* Microsomal protein per gram of liver (MPPGL) in paediatric biliary atresia patients. *Biopharm Drug Dispos.* **35**, 308–312 (2014).
42. Guengerich, F. P., Martin, M. V., Sohl, C. D. & Cheng, Q. Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. *Nat Protoc.* **4**, 1245–1251 (2009).
43. Wang, X. F. *et al.* [Establishment of formula predicting adult standard liver volume for liver transplantation]. *Zhonghua Wai Ke Za Zhi.* **46**, 1129–1132 (2008).
44. Yuan, D. *et al.* Estimation of standard liver volume for liver transplantation in the Chinese population. *Transplant Proc.* **40**, 3536–3540 (2008).
45. Tassaneeyakul, W. *et al.* Co-regulation of phenytoin and tolbutamide metabolism in humans. *Br J Clin Pharmacol.* **34**, 494–498 (1992).
46. Li, G. F., Yu, G., Liu, H. X. & Zheng, Q. S. Ethnic-specific *in vitro-in vivo* extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges. *Clin Pharmacokinet.* **53**, 197–202 (2014).
47. Back, D. J., Tjia, J., Monig, H., Ohnhaus, E. E. & Park, B. K. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. *Eur J Clin Pharmacol.* **34**, 157–163 (1988).
48. Miners, J. O., Wing, L. M., Lillywhite, K. J. & Smith, K. J. Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. *Br J Clin Pharmacol.* **18**, 853–860 (1984).
49. Wilner, K. D. & Gardner, M. J. Cimetidine does not alter the clearance or plasma binding of tenidap in healthy male volunteers. *Br J Clin Pharmacol.* **39** Suppl 1, 21S–24S (1995).
50. Wing, L. M. & Miners, J. O. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. *Br J Clin Pharmacol.* **20**, 482–485 (1985).

Acknowledgements

This work was partly supported by the National Natural Science Foundation of China (No. 81473279), Science and Technology Innovative Scholar Program of Henan Province (No. 134200510019) and Scientific and Technical Innovation Team of Zhengzhou City (131PCXTD604). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

H.Q. designed the experiments. H.Z. and H.Q. wrote the manuscript. N.G., X.T., Y.F. and J.Z. performed the kinetic analysis. H.Z. and T.L. performed the *in vitro-in vivo* extrapolation. H.Z., Y.F., T.L., B.X., B.Q., J.G., H.L. and L.J. prepared the human liver microsomes. H.Z., N.G. and Q.W. performed the data analysis. J.Z., T.L., Y.F., B.X., B.Q., J.G. and H.L. collected the liver samples. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, H. *et al.* Content and activity of human liver microsomal protein and prediction of individual hepatic clearance *in vivo*. *Sci. Rep.* **5**, 17671; doi: 10.1038/srep17671 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>